CHEMED CORP

Chemed's capital structure is characterized by a low debt-to-equity ratio of 0.11, indicating a conservative leverage position relative to its equity base. The company maintains a current ratio of 0.85, suggesting that its current liabilities exceed its current assets, which could signal potential liquidity constraints in the short term. Free cash flow for the period was $71.1 million, reflecting a strong ability to fund operations and potentially return value to shareholders. The company's liquidity risk is assessed as high, primarily due to the current liabilities exceeding current assets and the negative net cash position after subtracting total debt. Profitability metrics show a return on equity (ROE) of 7.82% and a return on assets (ROA) of 4.32%. These figures are below the industry median for healthcare providers, indicating that Chemed is underperforming in terms of asset utilization and equity returns. The operating margin, calculated as operating income of $84.6 million on revenue of $657.5 million, is 12.86%, which is also below the industry median. This suggests that Chemed may be facing cost pressures or pricing challenges in its core hospice and plumbing services. Chemed's revenue is concentrated across two primary segments: VITAS hospice care and Roto-Rooter plumbing services. The VITAS segment is the dominant contributor, with hospice care being a high-margin, recurring service. The Roto-Rooter segment, while less capital-intensive, is more exposed to cyclical demand and geographic variability. The company's geographic exposure is not explicitly detailed in the input data, but the Roto-Rooter segment's reliance on franchisees and independent contractors suggests a broad but fragmented geographic footprint. The company's growth trajectory is expected to remain stable, with revenue growth projected to be in line with the industry. The outlook for the current fiscal year (FY) is neutral, with no significant changes in revenue or operating income expected. The next FY is also projected to show minimal growth, with the company likely to maintain its current market position. Historical revenue trends indicate a steady but modest growth rate, with the most recent quarter showing $657.5 million in revenue. Risk factors include regulatory compliance in both the healthcare and franchising sectors, as well as potential dilution from future equity offerings. The company has been flagged for dilution risk, with source documents mentioning the possibility of future offerings. The dilution potential is moderate, and the company has not indicated any immediate plans for a significant equity issuance. However, the risk of dilution remains a concern, particularly if the company needs to raise capital for expansion or to address any regulatory issues. Recent events include a demand letter from the Medicare Administrative Contractor (MAC) seeking repayment of $50.3 million, which could impact the company's cash flow and financial stability. Additionally, the company has been involved in regulatory compliance related to its franchising activities, particularly with the Federal Trade Commission (FTC). These events highlight the importance of regulatory compliance and the potential for financial and operational disruptions.